All News Cyclacel Pharmaceuticals, Inc.

Equities

CYCC

US23254L8019

Market Closed - Nasdaq Other stock markets 01:30:00 29/06/2024 am IST			5-day change	1st Jan Change
1.62 ^USD	-4.71%		-7.43%	-39.33%

26/06	Sector Update: Health Care Stocks Softer Late Afternoon	MT
26/06	Sector Update: Health Care Stocks Lower in Afternoon Trading	MT

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sector Update: Health Care Stocks Softer Late Afternoon	27/06	MT
Sector Update: Health Care Stocks Lower in Afternoon Trading	27/06	MT
Cyclacel Receives Notice of European Patent Grant for Plogosertib; Shares Rise	26/06	MT
Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions	26/06	CI
Cyclacel Pharmaceuticals : A phase 1 study evaluating the safety, pharmacokinetics, and efficacy of fadraciclib, an oral CDK2/9 inhibitor, in patients with advanced solid tumors and lymphoma	03/06	PU
Cyclacel Pharmaceuticals, Inc. Reports New Clinical Data at 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib?s Potential as Precision Medicine for Cancer	03/06	CI
Cyclacel Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05	CI
Transcript : Cyclacel Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 14, 2024	15/05
Earnings Flash (CYCC) CYCLACEL PHARMACEUTICALS Posts Q1 Revenue $29,000	15/05	MT
Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results	09/05	AQ
Cyclacel Pharmaceuticals, Inc. announced that it has received $8.000001 million in funding	02/05	CI
Top Midday Gainers	01/05	MT
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday Ahead of FOMC Meeting	30/04	MT
Cyclacel Pharmaceuticals, Inc. announced that it expects to receive $8.000001 million in funding	30/04	CI
Cyclacel Pharmaceuticals Withdraws Securities Offering SEC Filing	30/04	DJ
Cyclacel Pharmaceuticals : April 2024 Corporate Presentation	02/04	PU
Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib's Potential as a Precision Medicine for Cancer	01/04	CI
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	20/03	AQ
Transcript : Cyclacel Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 19, 2024	20/03
Earnings Flash (CYCC) CYCLACEL Posts Q4 Revenue $31,000	20/03	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Cyclacel Pharmaceuticals, Inc.

Equities

CYCC

US23254L8019

All News

Filters